Regulatory update: corporate governance and board requirements in Kazakhstan in the pharmaceuticals sector

Foreign pharmaceutical companies operating in Kazakhstan through a local subsidiary or joint venture now face materially revised corporate governance obligations. Amendments to the regulatory framework governing pharmaceutical entities – which intersect both Kazakhstan corporate law and the sector-specific licensing regime administered by the Ministry of Healthcare – have introduced new requirements for board composition, residency qualifications for executive officers, and mandatory compliance-committee structures for entities engaged in the import, distribution, and manufacture of medicines. For in-house counsel managing regional portfolios that include a Kazakhstan operating vehicle, these changes require a structured review of existing governance documents before the applicable transition periods expire.

Kazakhstan's pharmaceutical sector has historically been governed by a combination of general corporate law (applicable to LLPs and JSCs alike) and a dedicated pharmaceutical licensing framework administered centrally through the Ministry of Healthcare, with technical oversight delegated to the National Centre for Expertise of Medicines, Medical Devices and Medical Equipment (known by its Kazakh acronym DKFM). In recent periods, the Kazakhstani legislature and the Ministry have moved in parallel to tighten the governance overlay applied specifically to entities holding pharmaceutical licences – a category that captures the overwhelming majority of foreign-owned operating vehicles in this sector.

The principal changes fall into three areas.

First, board and supervisory body composition. Entities structured as joint-stock companies (JSCs) engaged in pharmaceutical activities are now subject to enhanced requirements regarding the proportion of independent directors on their supervisory boards. For JSCs with a foreign shareholder holding more than 25 per cent of voting shares, the minimum independent-director threshold has been raised, and at least one member of the supervisory board must hold verifiable expertise in healthcare regulation, pharmaceuticals, or a related life-sciences discipline. LLP structures – the preferred vehicle for most inbound investors in Kazakhstan – are not subject to the JSC supervisory board rules in the same form, but are required to maintain a collegial executive body (pravlenie) of at least two persons where the entity holds a pharmaceutical manufacturer's licence.

Second, residency and qualification requirements for key officers. The requirement for the chief executive officer (or general director, in LLP terminology) of a licensed pharmaceutical entity to hold Kazakhstani residency has been reinforced. Practically, this affects foreign-owned subsidiaries where the general director role has been fulfilled by a non-resident secondee from the parent group. Under the revised framework, the general director of a pharmaceutical licence-holder must be either a Kazakhstani national or a foreign national holding a permanent residency permit (vid na zhitelstvo) in Kazakhstan. An entity that does not satisfy this requirement during a licence renewal cycle faces risk of refusal or conditional renewal.

Third, compliance committee structures. Pharmaceutical entities meeting a defined turnover or staffing threshold are now expected to maintain a documented internal compliance function specifically addressing product quality, pharmacovigilance, and anti-corruption obligations under Kazakhstani law. The compliance function need not be a separate legal unit, but it must be documented in internal regulations, reflected in the corporate charter or the collegial-body statutes, and its head must be identifiable to the Ministry of Healthcare upon request.

The revised requirements apply to all licensed pharmaceutical entities registered in Kazakhstan, irrespective of the nationality of their shareholders. In practice, however, the impact falls most acutely on three categories of foreign-owned structure.

The first category is the wholly owned subsidiary of a European, Asian, or North American pharmaceutical group, typically structured as a Kazakhstani LLP. These entities commonly rely on a seconded general director from the parent jurisdiction, a practice that the residency requirement now complicates. The practical resolution – appointing a locally resident general director while maintaining parent-group oversight through internal delegation instruments – requires careful governance structuring to preserve the parent's operational control without triggering a de facto compliance failure.

The second category is the joint venture between a foreign pharmaceutical group and a Kazakhstani partner, typically structured as a JSC. These entities face the combined weight of the independent-director threshold and the sector-qualification requirement. Where the Kazakhstani partner's nominee directors do not hold life-sciences credentials, and where the foreign partner's nominees are non-resident, satisfying both requirements simultaneously requires advance planning on board-nominee selection.

The third category is the distributor or parallel-importer of foreign pharmaceutical products, registered as a Kazakhstani LLP and holding an import licence rather than a manufacturer's licence. For this category, the collegial executive body requirement and the compliance documentation obligation are the primary operational impacts – the residency rule for the general director applies here too, but the absence of a manufacturer's licence means the JSC supervisory-board rules do not engage.

Kazakhstan is a member of the Eurasian Economic Union (EAEU), and pharmaceutical regulation within the EAEU is subject to a degree of supranational harmonisation through the decisions of the EAEU Council and the Eurasian Economic Commission (EEC). EAEU pharmaceutical regulation covers matters such as Good Manufacturing Practice (GMP) inspections, medicinal product registration procedures, and the mutual recognition of marketing authorisations across member states (Russia, Belarus, Kazakhstan, Armenia, Kyrgyzstan). The corporate governance changes described in this article are, however, a matter of domestic Kazakhstani corporate and licensing law – they sit outside the scope of EAEU harmonisation and are not replicated in identical form across other EAEU member states. Foreign investors operating across the EAEU should not assume that compliance with Russian or Belarusian governance requirements for pharmaceutical entities satisfies the Kazakhstani domestic standard.

For companies with operating vehicles in both Kazakhstan and Russia, the governance requirements are therefore parallel but distinct. A single Russia-Kazakhstan compliance framework will not suffice without jurisdiction-specific tailoring.

[CTA: If your group holds a Kazakhstan pharmaceutical entity and your governance documents predate these changes, a structured review is advisable before the next licence renewal cycle. Make an enquiry: info@vetrovpartners.com | WhatsApp/Telegram: +7 (983) 510-38-76]

The practical steps available to in-house counsel depend on the entity structure and the proximity of the next licence renewal date. The following framework applies across the three affected categories described above.

Review the general director's residency status. Where the current general director of a Kazakhstan pharmaceutical entity does not hold Kazakhstani residency, the entity should assess whether to formalise a transition to a locally resident director or to obtain permanent residency status for the incumbent. This is a sequential process under Kazakhstani migration law: the individual must first hold a valid long-term work permit before applying for permanent residency, and the overall timeline can extend to twelve months or longer. Entities whose licence renewal falls within the next eighteen months should prioritise this step.

Audit the board or collegial executive body against the new thresholds. For JSC structures, the supervisory board composition should be verified against the independent-director percentage and the sector-qualification requirement. Where a gap exists, the options include recruiting an additional independent director with healthcare credentials, restructuring the remit of an existing director to qualify them under the sector-expertise criterion, or converting to an LLP structure (where the JSC supervisory board rules do not apply in the same form) – though the last option involves a more significant corporate restructuring exercise.

Document and formalise the compliance function. For entities that meet the turnover or staffing threshold, the compliance documentation obligation is the most operationally straightforward of the three areas to address. It requires updating the entity's internal regulations, ensuring the charter or collegial-body statutes reference the compliance function, and designating a named compliance officer or function head. Parent-group compliance frameworks can be adapted for this purpose, but must be translated into Kazakh and/or Russian and localised to reflect Kazakhstani law requirements – a document that references only EU or US regulatory standards will not satisfy the Ministry of Healthcare's expectations.

Coordinate licensing timelines with governance remediation. Kazakhstan pharmaceutical licences are subject to periodic renewal, and the Ministry of Healthcare has indicated that governance compliance will be assessed as part of the renewal process. Entities that allow their licence to lapse and then seek renewal while governance deficiencies remain unaddressed face a materially more difficult path than those that remediate in advance. Counsel familiar with both the corporate governance framework and the pharmaceutical licensing process in Kazakhstan is therefore essential at the intersection of these two workstreams.

"For foreign pharmaceutical groups with Kazakhstan subsidiaries, the intersection of the domestic corporate governance rules and the EAEU licensing framework creates a compliance gap that neither parent-group counsel nor EAEU specialists alone are positioned to close without local Kazakhstani input." — Aigerim Serikbayeva, Contributing Regional Analyst — Kazakhstan · EAEU Trade, Customs and Market Entry

For companies with parallel operations in Russia and Kazakhstan, the cross-border coordination dimension adds a further layer of complexity. Russian corporate law and the Russian pharmaceutical licensing regime impose their own governance and officer-qualification requirements, which differ in structure and procedure from the Kazakhstani rules. A company managing governance remediation across both jurisdictions simultaneously will require separate workstreams for each, with coordination at the group level to ensure that corporate restructuring steps taken in one jurisdiction do not inadvertently affect the compliance position in the other.

[CTA: Vetrov & Partners advises on cross-border matters involving Russia and the EAEU region, including coordination with trusted local counsel in Kazakhstan and other EAEU member states. If your group needs a joined-up approach to Russia-Kazakhstan governance, make an enquiry: info@vetrovpartners.com | WhatsApp/Telegram: +7 (983) 510-38-76]

• Market entry and company formation in Kazakhstan: a guide for foreign investors (/jurisdictions/kazakhstan/company-formation/)
• Corporate governance in Kazakhstan joint ventures: foreign shareholder protections (/jurisdictions/kazakhstan/corporate-jv/)
• Pharmaceutical licensing and regulatory compliance in Kazakhstan (/jurisdictions/kazakhstan/regulatory-licensing/)

Q: What specifically changed in Kazakhstan's pharmaceutical corporate governance rules?

A: Kazakhstan introduced enhanced board composition requirements for pharmaceutical JSCs (including a minimum independent-director proportion and a sector-expertise qualification for at least one supervisory board member), a reinforced residency requirement for general directors of licensed pharmaceutical entities, and a mandatory documented compliance function for entities meeting defined turnover or staffing thresholds. These changes apply under domestic Kazakhstani corporate and licensing law and are distinct from EAEU-level pharmaceutical harmonisation measures.

Q: Which foreign pharmaceutical companies are most affected by these requirements?

A: The changes affect all foreign-owned entities holding a Kazakhstani pharmaceutical licence. In practice, the most significant operational impact falls on three categories: wholly owned subsidiaries relying on non-resident seconded general directors; JSC joint ventures where board composition does not yet meet the independent-director and sector-expertise thresholds; and licensed distributors or importers that have not yet documented a formal internal compliance function. Companies with licence renewals within the next eighteen months should treat remediation as a near-term priority.

Q: Does EAEU membership mean that compliance with Russian pharmaceutical governance rules satisfies the Kazakhstan standard?

A: No. The corporate governance and officer-qualification requirements described here are matters of domestic Kazakhstani law and fall outside the scope of EAEU pharmaceutical harmonisation, which addresses GMP standards, product registration, and marketing authorisation mutual recognition rather than entity-level governance. A foreign company compliant with Russian pharmaceutical governance rules cannot assume equivalent compliance in Kazakhstan. Separate, jurisdiction-specific advice is required for each EAEU member state in which the group holds a licensed pharmaceutical entity.

Vetrov & Partners is a Russian boutique law firm established in 2009 and recognised by Pravo-300 for eight consecutive years. The firm advises foreign companies on cross-border matters involving Russia and the EAEU region, including coordination with trusted local counsel in Kazakhstan, Armenia, Kyrgyzstan, and other member states.

The firm's Corporate & Joint Ventures practice assists foreign shareholders in structuring and maintaining compliant operating vehicles across the EAEU, with particular focus on governance arrangements for entities subject to sector-specific licensing requirements. For EAEU-region mandates requiring Kazakhstani local counsel, the firm works with trusted partners qualified under Kazakhstani law.

We are a Russian-qualified law firm. For matters governed by Kazakhstani or other foreign law, we collaborate with trusted counsel in the relevant jurisdiction.

Enquiries: info@vetrovpartners.com | WhatsApp / Telegram: +7 (983) 510-38-76 | t.me/vitvetcom

This publication is provided for informational purposes only and does not constitute legal advice under Russian or any other applicable law. The information herein should not be relied upon as a substitute for professional legal counsel tailored to your specific circumstances. Vetrov & Partners is a Russian-qualified law firm. For matters governed by foreign law or requiring local admission in another jurisdiction, we collaborate with trusted counsel in the relevant jurisdiction. For advice regarding your particular situation, please contact info@vetrovpartners.com.

— Aigerim Serikbayeva Contributing Regional Analyst — Kazakhstan · EAEU Trade, Customs and Market Entry vetrovpartners.com/contributions/